<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/30/2022 3:32:02 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: a9c2ecf9-9056-42fc-a5a6-96d1482b2025 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:krbp="http://www.kiromic.com/20221123" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityCentralIndexKey" id="Tc_vOBvKZEO6kercdgh7ouiuA_2_1">0001792581</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:AmendmentFlag" id="Tc_UDRXxktZMku7VEqkkGUvAg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="krbp-20221123.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-23</xbrli:startDate><xbrli:endDate>2022-11-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_edb00520_1e92_4978_9203_15cab0125234"></a><a id="BigHand_Transcription"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:DocumentType" id="Narr_sIZ5m91sEEWo-ELpMR71ag"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_vTu30Ck5DU2pmWv61s7uOw"><b style="font-weight:bold;">November 23, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityRegistrantName" id="Narr_6RqGJ9YaYUu1RJlpWbt1YQ"><b style="font-weight:bold;">KIROMIC BIOPHARMA, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_9aa7816e_96b8_41a5_a781_666415155525"></a><a id="Tc_R0OZj_TDzku0foRMFlF-jw_2_0"></a><a id="Tc_FaZ1GyN0hU2eFMemZugp1Q_2_2"></a><a id="Tc_hhg5vppTUEuQdEb_Ivcfuw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_RUS4UmlkJE6rUCTXxhPNRw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.82%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityFileNumber" id="Tc_L3oRj4kVO0SzYibbXjVkJw_1_2"><b style="font-weight:bold;">001-39619</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityTaxIdentificationNumber" id="Tc_1uth9Gq8jUGFsikqmXOycQ_1_4"><b style="font-weight:bold;">46-4762913</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">(State or other jurisdiction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">of incorporation)</span></p></td><td style="vertical-align:top;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">(Commission</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">File Number)</span></p></td><td style="vertical-align:top;width:1.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">(IRS Employer</span><span style="font-size:11pt;"><br /></span><span style="font-size:11pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityAddressAddressLine1" id="Narr_UXJjx5rV0k2Memo7BJCgOA"><b style="font-weight:bold;">7707 Fannin Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityAddressAddressLine2" id="Narr_bSq3OV2rKkyTRJLgAAERVw"><b style="font-weight:bold;">Suite 140</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityAddressCityOrTown" id="Narr_ufYrGmqgGEKJ5QBvj1mWeQ"><b style="font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityAddressStateOrProvince" id="Narr_heFlDX44HEOPTg4JJhMJcA"><b style="font-weight:bold;">TX</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:EntityAddressPostalZipCode" id="Narr_evxn-PZC3EKuVFuNfN1kuQ"><b style="font-weight:bold;">77054</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">(Address of principal executive offices) (Zip Code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code&#160;<b style="font-weight:bold;background:#ffffff;">(</b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:CityAreaCode" id="Narr_gplX1eomW0KfYHWz8Ur2lw"><b style="font-weight:bold;background:#ffffff;">832</b></ix:nonNumeric><b style="font-weight:bold;background:#ffffff;">)&#160;</b><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:LocalPhoneNumber" id="Narr_8N3kLLMvFke5_TTHny7paA"><b style="font-weight:bold;background:#ffffff;">968-4888</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-24pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_fa70823f_c6f1_4e89_9c9a_a13603f06cad"></a><a id="Tc_ygVFds0aUUSsiO7hhXVMzQ_1_1"></a><a id="Tc_An3QpZUlKUmMkunD5e8Yrw_3_1"></a><a id="Tc_C6-GW71rhkaITR-0wI49-g_5_1"></a><a id="Tc_F1Do993V7EeWbOxf8Fi8JA_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_sAVypwQm60u9GWuoxZfVmw_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_YXoZa3RD_Uqc3sk_AD_TLA_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_38GAaFbXdUSjy8_4NYeyZA_5_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_3CcN7-Y_2kSt_azao_SoAw_7_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 18pt;"><span style="font-size:11pt;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_5a1855d2_097f_4c3b_a710_dc60a883cfc8"></a><a id="Tc_vt3TqqRazk-DVrAUuJx4UA_1_0"></a><a id="Tc_XMr1uyTAP0uG58dwISjmfg_1_2"></a><a id="Tc_O9thiEwBJUSBG6eIaec3fw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:Security12bTitle" id="Tc_GbjCen9mSU6bHbOpMW0jFw_2_0">Common Stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" name="dei:TradingSymbol" id="Tc_1d3iVIwL2kenDrxH96Jv1Q_2_2">KRBP</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_EnSx7wDFAESAmmza10yTrA_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr__VTxLgobaEWpOZOPFtBCEA"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="Duration_11_23_2022_To_11_23_2022_gxUPeQ9iykm5Ybg0ZqfMrw" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_jarv5ceWZ0ethuajjr47tg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:23.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b91e539e_7c5b_41dd_b87e_2b6a0f918962"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 3.01     Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 23, 2022, Kiromic BioPharma, Inc. (the &#8220;Company&#8221;) received a letter (the &#8220;Letter&#8221;) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) notifying the Company that it is not in compliance with the minimum stockholders&#8217; equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders&#8217; equity of at least $2,500,000 (the &#8220;Stockholders&#8217; Equity Requirement). In the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders&#8217; equity of $284,100, which is below the Stockholders&#8217; Equity Requirement for continued listing. Additionally, as of the date of the Letter, the Company did not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules, which include a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Letter has no immediate effect on the listing of the Company&#8217;s common stock and the Company&#8217;s common stock continues to trade on The Nasdaq Capital Market under the symbol &#8220;KRBP&#8221; subject to the Company&#8217;s compliance with the other continued listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the Letter, the Company has 45 calendar days, or until January 9, 2023, to submit a plan to regain compliance. If the plan is accepted by Nasdaq, an extension of up to 180 calendar days from November 23, 2022 may be granted for the Company to evidence compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company is considering available options to regain compliance with the Nasdaq Listing Rules and is actively seeking financing options that could be helpful in meeting the Stockholders&#8217; Equity Requirement. The Company expects to develop a plan for submission to Nasdaq. However, there is no assurance that the Company will be successful in developing a plan for compliance,  that the Company&#8217;s plan will be accepted, or even if it is accepted, that the Company will ultimately be able to regain compliance. If the Company submits a plan to regain compliance and it is not accepted, Nasdaq would permit the Company to appeal the decision to reject the Company&#8217;s proposed compliance plan to a Nasdaq Hearings Panel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:12pt -27pt 0pt 0pt;"><span style="font-size:11pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:23.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_07df5017_974a_49d4_9ab0_27b5d42df308"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:52.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:43.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:52.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Date: November 30, 2022</p></td><td colspan="2" style="vertical-align:top;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">KIROMIC BIOPHARMA,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:52.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">By: </p></td><td style="vertical-align:top;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">/s/ Daniel Clark </i></p></td></tr><tr><td style="vertical-align:top;width:52.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Daniel Clark</p></td></tr><tr><td style="vertical-align:top;width:52.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "krbp-20221123x8k.htm", "description": "8-K", "secsgml_size_bytes": 34917}]
{"company-data": {"conformed-name": "Kiromic Biopharma, Inc.", "cik": "0001792581", "assigned-sic": "2836", "irs-number": "464762913", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39619", "film-number": "221435605"}, "business-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054", "phone": "832-968-4888"}, "mail-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054"}, "former-company": {"former-conformed-name": "Kiromic, Inc.", "date-changed": "20191029"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
​
FORM
8-K
​
CURRENT REPORT
​
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
November 23, 2022
​
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
​
Delaware
001-39619
46-4762913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
7707 Fannin Street
,
Suite 140
Houston
,
TX
,
77054
(Address of principal executive offices) (Zip Code)
​
Registrant's telephone number, including area code
(
832
)
968-4888
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
KRBP
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
Emerging growth company
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
Item 3.01     Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
​
On November 23, 2022, Kiromic BioPharma, Inc. (the "Company") received a letter (the "Letter") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement). In the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders' equity of $284,100, which is below the Stockholders' Equity Requirement for continued listing. Additionally, as of the date of the Letter, the Company did not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules, which include a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.
​
The Letter has no immediate effect on the listing of the Company's common stock and the Company's common stock continues to trade on The Nasdaq Capital Market under the symbol "KRBP" subject to the Company's compliance with the other continued listing requirements.
​
Pursuant to the Letter, the Company has 45 calendar days, or until January 9, 2023, to submit a plan to regain compliance. If the plan is accepted by Nasdaq, an extension of up to 180 calendar days from November 23, 2022 may be granted for the Company to evidence compliance.
​
The Company is considering available options to regain compliance with the Nasdaq Listing Rules and is actively seeking financing options that could be helpful in meeting the Stockholders' Equity Requirement. The Company expects to develop a plan for submission to Nasdaq. However, there is no assurance that the Company will be successful in developing a plan for compliance,  that the Company's plan will be accepted, or even if it is accepted, that the Company will ultimately be able to regain compliance. If the Company submits a plan to regain compliance and it is not accepted, Nasdaq would permit the Company to appeal the decision to reject the Company's proposed compliance plan to a Nasdaq Hearings Panel.
​
​
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
Date: November 30, 2022
KIROMIC BIOPHARMA, INC.
​
By:
/s/ Daniel Clark
​
​
Name: Daniel Clark
​
​
Title: Chief Financial Officer
​
​
​
​
​
​